Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional ...

NEW YORK, NY, USA I April 28, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma ...

VYJUVEK was approved by the FDA in the United States in May 2023 and is also under review for approval by Japan’s Pharmaceuticals and Medical Devices Agency with a decision expected in 2H 2025.

Novel glycan-directed ADC shows preclinical activity in gastric cancer and potential to address underserved patient population ...

CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...

EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...

BOSTON, MA, USA I April 15, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug ...

WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine ...